Similar to CYPs, Phase II drug metabolic enzymes including UGTs, SULTs, and transporters (e.g., OATPs, MRPs) play various regulatory roles in NAFLD. The gene discussed is MRPS7; the disease is metabolic dysfunction-associated steatotic liver disease.